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Charlotte Andersson, MD, PHD,yz Ramachandran S. Vasan, MDyxkSEE PAGE 588H ypertension is an important cause of car-diovascular disease (CVD) and mortality.Hypertension is present in approximately
40% of adults in the United States, and it accounts
for 41% of all CVD deaths (1–3), with a similar burden
of disease in the rest of the world (4). Lowering blood
pressure (BP) with medications substantially reduces
the risk of CVD (5,6).
Hypertension is well controlled in about 60%
of patients in the United States (i.e., a systolic
BP <140 mm Hg and a diastolic BP <90 mm Hg) (3).
What should be done for the remaining 40%? Should
they be treated more aggressively with medications,
or is it enough that they are treated, even if their BP
are not “normalized”? Panelists from the Eighth Joint
National Committee recently stirred up controversy
by relaxing the BP treatment target to <150/90 mm Hg
among people $60 years of age, largely because they
found little evidence from randomized trials showing
that tighter BP control leads to better outcomes (7).
These recommendations have been criticized as
relying too much on trials, without considering other
forms of evidence.
In this issue of the Journal, Sim et al. (8) provide
more support for relaxing BP treatment targets. They*Editorials published in the Journal of the American College of Cardiology
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levels with the risk of end-stage renal disease and
mortality over 3 to 5 years of follow-up in individuals
who were diagnosed with hypertension in the Kaiser
Permanente Southern California health system. Their
analyses of nearly 400,000 individuals, 19% of whom
had ischemic heart disease and 30% of whom had
diabetes, showed a signiﬁcant J-shaped association
between actual (treated) BP levels and adverse out-
comes, mainly driven by the higher mortality associ-
ated with lower on-treatment BP levels. Their data
suggest that the lowest risk of the composite outcome
was at systolic BP of 137 mm Hg and a diastolic BP
of 71 mm Hg. BP either higher or lower than 130 to
139 mm Hg systolic and 60 to 79 mm Hg diastolic
were associated with increased risk of the composite
endpoint.Epidemiological studies of hypertensive, medically
untreated individuals have shown a graded increase
in CVD and mortality with higher BP levels, without
any evidence of any J-shaped curve (9,10). These
observations led to the argument that the “lower the
blood pressure, the better the outcomes.” However,
the associations from untreated individuals might
not apply to people treated for hypertension, and it
is obvious that driving BP too low with medications
can lead to adverse effects. So, a J-curve relationship
between on-treatment BP and mortality is plausible,
yet leaves unanswered the question of what levels of
systolic and diastolic BP are optimal.
There is a physiologic rationale for a J-shaped
relationship between treated BP and outcomes.
Hypertension may, to some extent, be a consequence
of high arterial stiffness, so overly aggressive BP
lowering can lead to orthostatic hypotension and
hypoperfusion of vital organs (11). Furthermore, with
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599long-standing uncontrolled or poorly controlled
hypertension, autoregulatory mechanisms adapt to
higher BP levels, so the threshold for hypoperfusion
of vital organs is shifted upward (12). Coronary
perfusion pressure can fall approximately 30%
from the normal value before the autoregulatory
mechanisms begin to fail in people without heart
disease (13). Among people with heart disease (such
as signiﬁcant coronary stenoses, left ventricular
hypertrophy, or tachycardia), the coronary artery ﬂow
reserve is usually reduced. These people may, there-
fore, be more sensitive to BP-lowering interventions.
Lowering diastolic BP below 80 to 85 mm Hg (or even
90 mm Hg) has been suggested to increase the risk of
myocardial infarction in some groups (13,14).
Available randomized trials have not convincingly
demonstrated improved mortality rates with aggres-
sive antihypertensive treatment (6,15). A collabora-
tive meta-analysis of several large, randomized
clinical trials did not demonstrate any signiﬁcant
effect on mortality from intensive lowering of
BP compared with standard BP-lowering targets
(although there were fewer major adverse cardiac
events with the intensive treatment) (6). These ob-
servations suggest that optimal BP targets may vary
widely for different patient groups, and that there
might be heterogeneity in outcomes associated with
tight BP control. Further evidence that tight BP con-
trol may be undesirable in some patients is provided
by a recent trial that randomized patients with dia-
betes and hypertension to a systolic BP target of <140
mm Hg versus <120 mm Hg and showed that patients
assigned to intensive treatment had greater declines
in total brain volume over 40 months (16).
Older patients and those with long-standing poorly
controlled hypertension may be more sensitive to
intensive BP-lowering treatment compared with
younger people with less comorbidity. Sim et al. (8)
elegantly demonstrated that the optimal BP levels
were lower for younger patients (younger than vs.
older than 70 years of age), for individuals with dia-
betes, and for patients with low comorbidity burden.
J-shaped curves for CVD and mortality have been
shown for some other risk factors, including alcohol
consumption (17), glycosylated hemoglobin levels forpatients with diabetes (18), and body mass index
(19,20). Although these associations are biologically
plausible, they might be due to “reverse causation”:
individuals with very low values of a risk factor might
be sicker and have advanced disease and hence
higher mortality. Patients with chronic diseases also
may have spontaneous BP reductions, as their con-
ditions worsen. Sim et al. (8) found that systolic BP
values fell 7 mm Hg in the 60 days before death.
Although the J-shaped relation remained evident
even when these pre-mortality BP values were
omitted from the analysis, a much longer phase of
BP reduction before death would not have been
adequately addressed by the analysis. In an analysis
of individual patient data from 7 randomized clinical
trials of blood pressure lowering, Boutitie et al. (21)
also found an increased risk of mortality among
patients with low blood pressure values, which was
not related speciﬁcally to antihypertensive treat-
ment, suggesting that comorbid conditions might
explain the J-shaped mortality curve.
Ultimately, we need further studies to establish
the optimal BP treatment target for patients with
various comorbidities. It may make sense to treat
younger people with less comorbidity more aggres-
sively than older patients or people with a large
burden of comorbidity, but the exact numerical BP
targets are yet to be determined. Clinical trial results
would provide a more deﬁnitive answer than obser-
vational analyses will, even analyses of very large
datasets. The ongoing SPRINT (Systolic Blood Pressure
Intervention Trial), which randomizes people with
hypertension to a systolic BP of <140 mm Hg or <120
mm Hg, should provide key data on targets. Truly
uncontrolled hypertension, even on the basis of the
looser targets recommended by the Eighth Joint Na-
tional Committee, remains a challenge, and we still
must be concerned about undertreatment of hyper-
tension, even as we sort out the optimal treatment
target.
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